Projekte
Suche in 1158 Projekten:
1158 Projekt(e)
IDN-6556-14 NASH und Emricasan
14.09.2016A Multicenter, Randomized, Double-Blind, Placebo- Controlled Trial of Emricasan, an Oral Caspase Inhibitor, in Subjects with Non-Alcoholic Steatohepatitis (NASH) Cirrhosis and Severe Portal Hypertension
Klinische Forschung - 14.09.2016 - 14.09.2021
Abgebrochen
Projektleitung: Semela David
Mitarbeiter/innen: Alfter Christine
SASL 38 Swiss Cohort Study on Autoimmun Hepatitis
14.09.2016Research project in which biological material is sampled from humans and health-related personal data is collected for research.
Klinische Forschung - 14.09.2016 - 14.09.2022
Automatisch geschlossen
Projektleitung: Semela David
Mitarbeiter/innen: Stillhard Roman
SASL 39 Swiss Cohort Study on Primary Biliary Cholangitis
14.09.2016Research project in which biological material is sampled from humans and health-related personal data is collected for research.
Klinische Forschung - 14.09.2016 - 14.09.2022
Automatisch geschlossen
Projektleitung: Semela David
Mitarbeiter/innen: Stillhard Roman
A 52-week, multicenter, randomized, double-blind, placebocontrolled study to assess the efficacy and safety of QAW039 when added to existing asthma therapy in patients with uncontrolled severe asthma
11.09.2016Das Ziel dieser Studie ist es, die Wirksamkeit und Sicherheit von QAW039 (150 mg und 450 mg einmal täglich) im Vergleich zu Placebo zu bestimmen, wenn es Patienten mit unzureichend kontrolliertem schweren Asthma und hoher Anzahl an Eosinophilen (Eosi...
Klinische Forschung - 11.09.2016 - 31.03.2018
Automatisch geschlossen
Projektleitung: Brutsche Martin
Mitarbeiter/innen: Baty Florent, Schlotter Sandra
CA209451: Randomized, Multicenter, Double-Blind, Phase 3 Study of Nivolumab, Nivolumab in Combination with Ipilimumab, or Placebo as Maintenance Therapy in Subjects with Extensive-Stage Disease Small Cell Lung Cancer (ED-SCLC) after Completion of Platinum-based First Line Chemotherapy. CheckMate 451
07.09.2016This is a randomized, double-blind, three-arm, multicenter, Phase 3 study in adult subjects with ED-SCLC, who achieve Stable Disease, Partial Response or Complete Response after completion of platinum based first line chemotherapy. Approximately 810...
Klinische Forschung - 07.09.2016 - 30.11.2020
Automatisch geschlossen
Projektleitung: Früh Martin
Monitoring of Patients’ Needs, Professional Triggers and delivered Basic Palliative Care Interventions in Routine inpatient and ambulatory of Advanced Incurable Cancer Patients: A sub-study to pilot the clinical practice tool – ESMO patient guide with KIPCC log
01.09.2016Increasing evidence from randomized studies (Level A) shows that quickly integrated palliative care interventions in the treatment of cancer patients may improve the quality of life of patients and relatives, illness and prognosis understanding and s...
Klinische Forschung - 01.09.2016 - 31.03.2017
Automatisch geschlossen
Projektleitung: Strasser Florian
Mitarbeiter/innen: Domeisen Benedetti Franzisca
REGAIN CONTROL Toujeo
01.09.2016Eine 26-wöchige, randomisierte, offene, zweiarmige, pragmatische Parallelgruppenstudie unter realen Bedingungen zur Beurteilung des klinischen und gesundheitsrelevanten Nutzens des Wechsels zu Toujeo® im Vergleich zum als Therapiestandard geltenden I...
Klinische Forschung - 01.09.2016 - 14.03.2018
Abgeschlossen
Projektleitung: Aczel Stefan
Mitarbeiter/innen: Räss Andrea
An open-label Phase 1/2a study of BAL101553 adminis-tered as 48-hour intravenous infusions in adult patients with advanced solid tumors
19.08.2016The primary objectives of this study are to determine the maximum tolerated dose (MTD) and to characterize dose-limiting toxicities (DLTs) of BAL101553, administered as an intravenous (IV) infusion over 48 hours on study Days 1, 8 and 15 of a 28-day...
Klinische Forschung - 19.08.2016 - 31.01.2018
Automatisch geschlossen
Projektleitung: Jörger Markus
BI1199.214 Senscis
09.08.2016A double blind, randomised, placebo-controlled trial evaluating efficacy and safety of oral nintedanib treatment for at least 52 weeks in patients with ‘Systemic Sclerosis associated Interstitial Lung Disease’(SSc-ILD). A trial to compare nintedanib...
Klinische Forschung - 09.08.2016 - 08.09.2017
Abgeschlossen
Projektleitung: Müller Rüdiger
Mitarbeiter/innen: Forrer Silvia, Bartz-Batliner Mira, Hutz Carina Liane, Schmidig Kathrin
Entyvio PASS Study
28.07.2016Entyvio (vedolizumab) long-term safety study: An international observational prospective cohort study comparing vedolizumab to other biologic agents in patients with ulcerative colitis or Crohn’s Disease. This is a prospective, observational, multi-...
Klinische Forschung - 28.07.2016 - 28.06.2022
Automatisch geschlossen
Projektleitung: Brand Stephan
Mitarbeiter/innen: Dora Barbara, Knellwolf Christina, Sulz Michael, Krieger-Grübel Claudia
Phase II Trial of Pembrolizumab (MK-3475) in Subjects with Metastatic Castration-Resistant Prostate Cancer (mCRPC) Previously Treated with Chemotherapy (KEYNOTE-199) / MK-3475-199 Pembro Prostata
27.07.2016This is a nonrandomized, multinational, open-label trial of pembrolizumab (MK-3475) in subjects with metastatic cas-tration-resistant prostate cancer (mCRPC) previously treated with docetaxel-based chemotherapy. The trial will be conducted in conform...
Klinische Forschung - 27.07.2016 - 30.06.2019
Automatisch geschlossen
Projektleitung: Omlin Aurelius
A Phase 1/2a Dose Escalation and Cohort Expansion Study for Safety, Tolerability, and Efficacy of BMS-986156 Administered Alone and in Combination with Nivolumab (BMS-936558, anti PD-1 Monoclonal Anti-body) in Advanced Solid Tumors
21.07.2016This is a Phase 1/2a, open-label study of BMS-986156 administered as a single agent and in combination with nivolumab in subjects with advanced solid tumors. The study will be conducted in 4 parts. Parts A and B will consist of dose escalation with B...
Klinische Forschung - 21.07.2016 - 30.09.2017
Automatisch geschlossen
Projektleitung: Jörger Markus
Immunmonitoring of patients before, during and after immunotherapy to predict anti-tumor response in melanoma and non-small cell lung cancer (IMIT)
15.07.2016
Klinische Forschung - 15.07.2016 - 15.10.2019
Automatisch geschlossen
Projektleitung: Flatz Lukas
Mitarbeiter/innen: Diem Stefan
Constructing accessory lymph nodes in situ for control of mammary carcinoma
01.07.2016Lymph nodes (LNs) are situated at junctures of the blood vascular and the lymphatic system where antigens drain from peripheral tissues via afferent lymphatics. The decision whether and how immune responses against tumors are initiated and maintained...
Grundlagenforschung - 01.07.2016 - 30.06.2019
Automatisch geschlossen
Projektleitung: Ludewig Burkhard
Mitarbeiter/innen: Cupovic Jovana
A multicentre, double blind, randomised, placebo-controlled, Phase II trial to evaluate Resminostat for maintenance treatment of patients with advanced stage (Stage IIB-IVB) mycosis fungoides (MF) or Sézary Syndrome (SS) that have achieved disease control with systemic therapy – the RESMAIN Study
25.06.2016
Klinische Forschung - 25.06.2016 - 31.12.2027
Laufend
Projektleitung: Cozzio Antonio
eSATIS: Early Sleep Apnea Treatment in Stroke: A Randomized, Rater-Blinded, Clinical Trial of Adaptive Servo-Ventilation
20.06.2016The prevalence of Sleep Disordered Breathing (SDB) after acute stroke is high (over 50% of affected patients in more than 20 studies). SDB after stroke has been found to be associated with a faster progression of stroke severity, with higher blood pr...
Klinische Forschung - 20.06.2016 - 20.06.2018
Automatisch geschlossen
Projektleitung: Flügel Dominique
Mitarbeiter/innen: Kägi Georg
AdaptResponse
17.06.2016Studie mit einem System für die kardiale Resynchronisationstherapie (CRT - Cardiac Resynchronization Therapy) mit der aCRT-Funktion zur optimierten Behandlung von Herzinsuffizie
Klinische Forschung - 17.06.2016 - 31.12.2022
Abgeschlossen
Projektleitung: Ammann Peter
Mitarbeiter/innen: Vetsch Susanne
An Open Label Biomarker Driven Phase II Clinical Trial of Abiraterone Acetate (AA) Re-Challenge in Patients with Metastatic Castration-Resistant Prostate Cancer and Prior Response to AA (Abi-RE)
12.06.2016Clinical Trial with an IMP, risk category B according to HRA. Abiraterone acetate (AA) is a standard treatment option both in chemotherapy naïve and docetaxel pre-treated men with metastatic castrate-resistant prostate cancer (CRPC). With the approva...
Klinische Forschung - 12.06.2016 - 31.12.2017
Automatisch geschlossen
Projektleitung: Omlin Aurelius
SAKK GRAALL 2014: Multicenter trial for the treatment of Acute Lymphoblastic Leukemia (ALL) in younger adults (18-59 years)
03.06.2016GRAALL-2014 follows the GRAALL-2003 and 2005 trials. The GRAALL-2014 trial is subdivided in three sub-studies: GRAALL-2014/B, GRAALL-2014/T and GRAAPH-2014respectively for patients with B-lineage Ph-negative ALL, T-lineage ALL or Ph+ ALL. France, S...
Klinische Forschung - 03.06.2016 - 31.05.2026
Laufend
Projektleitung: Silzle Tobias
Mitarbeiter/innen: Quinter Janine
A Prospective, Multicenter, Observational, Single-arm European Registry on the ACE Reperfusion Catheters and the Penumbra System in the Treatment of Acute Ischemic Stroke
02.06.2016Study Objective: To observe the safety and effectiveness of the ACE Reperfusion Catheters and the Penumbra System in patients with acute ischemic stroke from large vessel occlusion, treated with the ADAPT technique in site routine practice. Study De...
Klinische Forschung - 02.06.2016 - 31.05.2017
Abgeschlossen
Mitarbeiter/innen: Vehoff Jochen, Kägi Georg, Müller Anna